使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之組成物和方法农业专利-农业学术服务平台

发明人:: HAMDY, AHMED,海姆第阿曼,海姆第阿曼,ROTHBAUM, WAYNE,罗斯包姆维尼,羅斯包姆維尼,IZUMI, RAQUEL,伊兹米瑞奎尔,伊茲米瑞奎爾,LANNUTTI, BRIAN,雷努提布莱恩,雷努提布萊恩,COVEY, TODD,克维陶德,克維陶德,ULRICH, ROGER,尔理罗杰,爾理羅傑,JOHNSON, DAVE,强森德夫,強森德夫,BAR

摘要：: Therapeutic methods and pharmaceutical compositions for treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are described. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating subtypes of CLL and SLL using a BTK inhibitor, including subtypes of CLL in patients sensitive to thrombosis and subtypes of CLL that increase monocytes and NK cells in peripheral blood after treatment with a BTK inhibitor. In certain embodiments, the invention includes pharmaceutical compositions for treating hematological malignancies comprising a combination of a BTK inhibitor and an anti-CD20 antibody.本發明說明用於治療慢性淋巴球性白血病(CLL)和小淋巴球性白血病(SLL)之治療方法和醫藥組成物。在某些實施態樣中,本發明包括使用BTK抑制劑以治療CLL和SLL之治療方法。在某些實施態樣中,本發明包括使用BTK抑制劑以治療CLL和SLL的亞型之治療方法,該等亞型包括對血栓形成敏感之病患的CLL亞型及經BTK抑制劑治療之後增加末梢血液中單核球和天然殺手(NK)細胞之CLL亞型。在某些實施態樣中,本發明包括用於治療血液惡性疾病之醫藥組成物,其包含BTK抑制劑與抗CD20抗體之組合。